Stress-induced hyperglycaemia occurs very frequently in critically ill patients. A significant proportion of critically ill patients admitted to the intensive care unit (ICU) have been previously diagnosed as diabetic or have undiagnosed diabetes [1] [2] .
Since the first study by Van den Berghe et al 3 , most centres have adopted some kind of routine glycaemic control protocol. Several intensive treatment protocols have been previously published, with variable results and complication (hypoglycaemia) rates. In their initial study, Van den Berghe et al demonstrated that intensive insulin therapy -maintenance of blood glucose concentrations between 2.2 and 6.1 mmol/l -significantly reduced the incidence of bloodstream infections, polyneuropathy, the need for dialysis and transfusions and mortality among critically ill patients in a surgical ICU 3 . Subsequently, medical patients received the same protocol and a reduction in morbidity was also detected. Acute renal failure was prevented, the time under mechanical ventilation was shortened and the time spent in the ICU and in the hospital was reduced 4 . The frequency of severe hypoglycaemia in these studies was 5.1 and 18.7%, respectively. Recently, however, two studies -VISEP 5 and GLUControl 6were prematurely discontinued due to the elevated rates of hypoglycaemia in patients undergoing tight glucose control and because of an apparent lack of benefit associated with this strategy. Krinsley and Grover recently demonstrated that hypoglycaemia was independently associated with an increased risk of death in critically ill patients 7 SUMMARy Intensive insulin treatment is associated with an increased risk of hypoglycaemia. The purpose of this study was to evaluate two different strategies: tight glucose control (TGC) versus intermediate glucose control (IGC) . In this quasiexperimental study, 130 critically ill patients were assigned to receive either the TGC protocol (n=65), according to which blood glucose levels were maintained between 4.4 and 6.1 mmol/l, or the IGC protocol (n=65), according to which blood glucose levels were maintained between 4.4 and 8.0 mmol/l. A total of 52 subjects (40%) were diabetic and 63 (49%) were septic. In the IGC group, glucose levels were stabilised in the target range for a longer period of time when compared to the TGC group (63 vs 41%, P <0.001). The median capillary blood glucose level was 6.7 mmol/l in the TGC group (6.2 to 7.2) and 7.9 mmol/l (7.0 to 8.5) in the IGC group (P <0.001). The incidence of hypoglyacemia less than 2.2 mmol/l was 21.5% in the TGC group and 1.5% in the IGC group (P <0.001), and the incidence of hypoglycaemia less than 3.3 mmol/l was 67.7 and 26.2% (P <0.001) in the two groups, respectively. Diabetes (odds ratio 2.88, CI 1.22 to 6.84) and the TGC protocol (odds ratio 7.39, CI 3.15 to 17.35) were identified as independent risk factors for hypoglycaemia less than 3.3 mmol/l. Mechanical ventilation (odds ratio 4.33, CI 1.16 to 16.13) , medical illness (odds ratio 2.88, CI 1.20 to 6.99) and hypoglycaemia (<3.3 mmol/l) (odds ratio 2.99, CI 1.21 to 7.41) were independent factors associated with mortality. TGC is difficult to accomplish in routine intensive care unit settings and is associated with a significant increase in the incidence of hypoglycaemia. Hypoglycaemia <3.3 mmol/l is an independent risk factor for in-hospital mortality.
increased hypoglycaemia may tend to neutralise benefits of strict glycaemic control.
It seems possible that a safer and more gradual approach to glucose control, as was recently suggested 8 , will be interesting. Therefore, we chose to evaluate both strategies, primarily by comparing the occurrence of hypoglycaemia and glycaemic control in patients admitted to a general ICU.
METHoDS
This is a quasi-experimental study (before:after design) that was conducted as part of the best practice improvement project of the Hospital Israelita Albert Einstein ICU, in São Paulo, Brazil. This hospital is a 500-bed, private, general hospital, and its 32-bed adult ICU admits medical and surgical patients from all specialties. The nurse to patient ratio is 1:2. The patient care team includes respiratory therapists, clinical pharmacists and psychologists. Medical and surgical intensive care specialists supervise the patients 24 hours a day.
After a consensus was reached among the critical patient division, endocrinology division, nursing department and the clinical pharmacy division, we implemented the intravenous insulin protocol, based on a study by Kanji et al 9 , with the purpose of maintaining blood glucose levels between 4.4 and 6.1 mmol/l (tight glucose control [TGC] group). All patients admitted to the ICU from August 2006 to March 2007, who demonstrated capillary glucose levels >6.1 mmol/l on three consecutive measurements and who were receiving continuous caloric intake, were enrolled in this study. Individuals who received the protocol for less than 24 hours were excluded from the final analysis.
After data collection was completed and the number of episodes of severe hypoglycaemia had been analysed (<2.2 mmol/l), the committee responsible for the study decided to maintain the same protocol; however, the target blood glucose concentration range was widened to between 4.4 and 8.0 mmol/l (intermediate glucose control [IGC] group). In the second phase of the study, which occurred between July 2007 and February 2008, all patients who demonstrated capillary glucose levels >8.0 mmol/l on three consecutive measurements and who were receiving continuous caloric intake were included in the study. Individuals who received the protocol for less than 24 hours were excluded from the final analysis.
This study was approved by the local institutional review board and the insulin infusion protocol was approved by the medical practice committee. As this study was part of the previously approved insulin infusion protocol and did not involve any additional patient interventions, the requirement for informed consent was waived.
Insulin doses were adjusted by the ICU nurses based on capillary blood glucose levels. Blood was obtained from each patient's fingertip using a lancet and glucose levels were measured using the MediSense Precision PCx, A device (ABBoTT Laboratories, Bedford, MA, USA).
Clinical and demographic data were collected, as well as Acute Physiology and Chronic Health Evaluation II (APACHE II) score, the type of nutritional support and the use of steroids. Protocol information was registered, along with baseline glucose levels, insulin dose and time to reach and time spent within the target blood glucose range. Glycaemic variability, defined as the standard deviation of the mean glucose levels for each patient after the onset of the insulin infusion protocol, was analysed. The incidence of hypoglycaemia <3.3 mmol/l, hypoglycaemia <2.2 mmol/l and outcomes (in-hospital mortality) were also analysed. In order to examine age and illness severity as risk factors associated with mortality and hypoglycaemia, patients were divided into groups based on age (≥60 years) and APACHE II score (≥20).
Statistical analysis
Continuous variables were compared using Student's t-test for normally distributed variables and the Kruskal-Wallis test for non-normally distributed variables. Differences in proportions were compared using chi-square test or Fisher's exact test, where appropriate. Alpha was set at 0.05 and all tests of significance were two-tailed. The significant variables for hypoglycaemia (glucose values <3.3 mmol/l) in the univariate analysis were entered into a logistic regression model. When co-linearity was identified between two variables in a correlation matrix, the one with the greater clinical relevance associated with the risk for hypoglycaemia (glucose values <3.3 mmol/l) was included in the multivariate analysis. The Hosmer and Lemeshow goodness-of-fit statistic was used to assess adequacy of the model fit. odds ratios (oR) with 95% confidence intervals (CI) were calculated for the independent variables associated with hypoglycaemia (glucose value less than 3.3 mmol/l). A second logistic regression analysis for mortality was also performed considering the previous statistical fundamentals described for the hypoglycaemia analysis (glucose value less than 3.3 mmol/l). All statistical analyses were performed using the Statistical Package for the Social Sciences software (SPSS version 11.5, Chicago, IL, USA).
RESULTS

Patients
A total of 130 patients, divided into two groups of 65 each, were evaluated. Most of the patients were men (n=86, 66%); 72 (55%) were medical patients and 58 (45%) were surgical patients. The main reason for ICU admittance was respiratory failure (25%), followed by solid organ transplantation (18%) and abdominal pathology (17%). A total of 52 patients (40%) had a history of diabetes and 63 patients (49%) were septic. Seventy-seven patients (59%) were receiving vasopressor agents and 95 (73%) were under mechanical ventilation. The main demographic, clinical and therapeutic data are reported in Table 1 .
Protocols
The total treatment time of the TGC protocol was 13,503 hours (a mean of 207 hours per patient), while the total time of the IGC protocol was 8397 hours (a mean of 135 hours per patient). A total of 11,436 capillary blood glucose measurements were performed in the TGC group (a mean of one measure every 1.2 hours) and a total of 6318 measurements were performed in the IGC group (a mean of one measure every 1.3 hours). At the onset of the insulin 
Complications
A total of 14 patients (21.5%) in the TGC group presented capillary glucose levels lower than 2.2 mmol/l versus one patient (1.5%) in the IGC group (P <0.001). Three subjects in the TGC group presented two episodes of hypoglycaemia (<2.2 mmol/l), while only one patient in the IGC group presented two episodes of hypoglycaemia <2.2 mmol/l. In the TGC group, the mean capillary glucose level during the hypoglycaemia episodes (n=17) was 1.9±0.27 mmol/l. These episodes occurred between two and 360 hours after the onset of continuous insulin infusion (mean of 123±111 hours). In the IGC group, the capillary glucose levels during the hypoglycaemia episodes were 2.0 and 1.7 mmol/l (n=2), and these episodes occurred 16 and 51 hours after the onset of the protocol. No seizures were observed during the hypoglycaemia episodes. one patient presented hypotension and another psychomotor agitation. During one episode of hypoglycaemia (<2.2 mmol/l), we observed that the insulin infusion was not interrupted when caloric infusion was temporarily ceased. The protocol data and the hypoglycaemia incidences are shown in Table 2 .
Predisposing factors for hypoglycaemia and mortality
A logistic regression analysis was conducted for hypoglycaemia <3.3 mmol/l ( Table 3 ). In this sample, a history of diabetes (oR 2.88, CI 1.22 to 6.84) and use of the TGC protocol (oR 7.39, CI 3.15 to 17.35) were identified as independent risk factors for hypoglycaemia <3.3 mmol/l. Table 4 shows the analysis of risk factors for mortality. The use of mechanical ventilation (oR 4.33, CI 1.16 to 16.13), medical disease (oR 2.88, CI 1.20 to 6.99) and hypoglycaemia <3.3 mmol/l (oR 2.99, CI 1.21 to 7.41) were identified as independent risk factors for mortality.
DISCUSSIoN
In this study, we initially assessed the implementation of tight glucose control (4.4 to 6.1 mmol/l) in patients admitted to an ICU. We compared these results to those from the intermediate glucose control protocol (4.4 to 8.0 mmol/l) that was subsequently adopted. Most patients were elderly, had infections, were sedated and under mechanical ventilation, and were receiving vasopressor agents and enteral feeding. A significant proportion of these patients were diabetic, were undergoing dialysis and presented with underlying liver disease. The main reason for admittance to the ICU was respiratory failure, followed by solid organ transplantation.
Recent studies indicate that glycaemic variability may influence the outcomes of patients admitted to the ICU. Egi et al showed that the standard deviation of blood glucose concentration was an independent predictor of ICU and hospital-related mortality 10 . Ali et al demonstrated that greater glycaemic variability was associated with poor outcomes in patients diagnosed with sepsis 11 . Krinsley demonstrated that higher glycaemic variability values were associated with higher mortality rates in a heterogeneous ICU population 12 . In this study, even though the groups differed in their mean blood glucose concentration values, there was no statistically significant difference between the groups regarding glycaemic variability (standard deviation of mean glucose values). In our study, this variable was higher than reported in other recent studies 13 . This difference may be a consequence of the metabolic instability of our patients due to their underlying conditions (e.g. diabetes, sepsis, liver failure) and the treatments that they received (e.g. vasopressor support, dialysis, steroids). Hypoglycaemia represents one of the main problems of intensive insulin treatment. It is frequently defined as blood glucose levels lower than 2.2 mmol/l and the majority of studies do not report data about less severe episodes of hypoglycaemia (glycaemic levels lower than 3.3 mmol/l) or possible associated adverse events. Some previous studies reported a low incidence of hypoglycaemia 3, 14 , while others detected high levels of hypoglycaemia and were prematurely discontinued [5] [6] . In our study, the patients in the TGC group presented a 14-fold increase in hypoglycaemia <2.2 mmol/l and an almost three-fold increase in hypoglycaemia <3.3 mmol/l. Data analysis indicated that a history of diabetes and the use of the tight glucose control protocol (4.4 to 6.1 mmol/l) were independent risk factors for the occurrence of hypoglycaemia <3.3 mmol/l. Vriesendorp et al reported that diabetes and other factors (female gender, haemofiltration, sepsis, shock, decreased nutrition without insulin adjustment) were associated with an increase risk of hypoglycaemia 15 . Krinsley and Groover showed that, in addition to diagnosis of diabetes and tight glucose control, APACHE score and mechanical ventilation were also risk factors associated with hypoglycaemia 7 . Since a clear relationship between hyperglycaemia and mortality in diabetic ICU patients has not yet been established 16 , the use of intensive insulin treatment protocols for these patients must be carefully considered due to the risk of hypoglycaemia and the potential lack of beneficial effects 17 .
The NICE-SUGAR study 18 results were reported after the end of our study. This large, international, randomised trial showed that intensive glucose control increased mortality among adults in the ICU, conflicting with the Leuven studies results. When compared with the NICE-SUGAR study, our patients had a higher APACHE II score, higher incidence of diabetes and use of renal replacement therapy. It is possible that all these factors commented above and the computerised treatment algorithm which was not applied in our study, could justify our higher incidence of hypoglycaemia.
In our study, multivariate analysis identified mechanical ventilation, medical disease and hypoglycaemia <3.3 mmol/l as independent risk factors for mortality. The consequences of hypoglycaemia in critically ill patients have not yet been clearly elucidated. Hypoglycaemia may simply be a marker of the illness severity 19 . Recently, one study showed that hypoglycaemia was an independent risk factor for mortality 7 ; however, a previous study did not show the same result 20 . Until this issue is clarified, all efforts and precautions must be undertaken to reduce the incidence of hypoglycaemia 21 .
There are several limitations to this study. First, there was no randomisation, there were significant differences between APACHE II score and steroid use in the patients in the TGC group, and a greater number of older patients with higher rates of vasopressor use in the IGC group. Second, due to the observational nature of this study, protocol implementation occurred in routine ICU settings, without the influence of the study team. Third, we did not monitor patient caloric intake or daily steroid dose. Fourth, the inherent nature of a before:after study and the absence of intention-totreat type analysis may be a potential source for bias. Finally, capillary blood and bedside point-of-care were used for glucose measurements. This system presents some limitations; data suggest that fingerstick and point-of-care glucose measurements are inaccurate and tend to overestimate the actual, blood glucose levels in critically ill ICU patients 22, 23 . However, although it is not considered the gold standard, it was the most practical and rapid approach that was available 24 .
our data indicate that tight glucose control, within the 4.4 to 6.1 mmol/l range, was hard to achieve in our routine ICU setting and that patients remained out of this target range much of the time. Here, TGC achieved a lower mean glucose level but a significant increase in the incidence of hypoglycaemia was also observed. An intermediate approach, which aims for glucose levels in the range of 4.4 and 8.0 mmol/l (IGC), was safer but was associated with higher glucose levels.
